Background: Traumatic brain injury (TBI) results in a significant morbidity and mortality. Several inflammatory mediators are released after TBI. Some studies have shown inconclusive association between interleukin-6 (IL-6) and outcome following TBI.
Aims and Objectives: The aim of the present study was to investigate the role of plasma IL-6 levels as a possible prognostic marker in patients with severe TBI.
Materials and Methods: A total of 47 male patients with isolated severe TBI were included in a prospective observational study. Plasma IL-6 levels was measured at admission, 24 h and 48 h. Association of IL-6 levels with mortality and functional outcome were studied. The Glasgow outcome scale was used to assess functional outcomes.
Results: Mean age was 44.4 years. Overall mortality of 42.6% was noted. Higher mortality was noted for patients beyond 50 years of age. Mean IL-6 levels at the time of admission was 306.285 pg/mL and 167.830 pg/mL at 24 h while 99.033 pg/mL at 48 h of admission Mean IL 6 levels were higher in patients with lower Glasgow coma scale (GCS), with a significant statistical association of GCS with IL-6 levels at admission and 24 h (P<0.001). 38 (80.85%) patients underwent surgical intervention. No statistical correlation was noted between IL-6 levels and mode of management. Significant IL-6 levels were seen in patients with worse clinical course at admission, 24 h and 48 h (P<0.0001). A level of 78 pg/mL was the appropriate cutoff to differentiate patient mortality as per receiver operating characteristic curve with Sensitivity of 1 and specificity of 0.8.
Conclusion: IL-6 plasma concentrations are likely to be a useful parameter for assessing prognosis in severe TBI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.